bioXXmed AG (HAM:T5O) Beta: 0.4911 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:T5O bioXXmed AG HAM:T5O
33 GF Score
Price €0.77
GF Value €9.07
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioXXmed AG Beta?

bioXXmed AG HAM:T5O 33 Beta is 0.4911 as of Jul. 16, 2026. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-16), bioXXmed AG's Beta is 0.4911.


bioXXmed AG  (HAM:T5O) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


bioXXmed AG Beta Related Terms


bioXXmed AG Beta Historical Data

* Premium members only.

The historical data trend for bioXXmed AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioXXmed AG Beta Chart

bioXXmed AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.69 3.29 2.86 2.88

bioXXmed AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.29 3.36 2.86 2.55 2.88

HAM:T5O vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, bioXXmed AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioXXmed AG Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bioXXmed AG's Beta distribution charts can be found below:

* The bar in red indicates where bioXXmed AG's Beta falls into.


HAM:T5O
33GF Score
bioXXmed AG HAM:T5O
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

bioXXmed AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4911 mean?
bioXXmed AG (HAM:T5O) has a Beta of 0.4911 as of Jul. 16, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for bioXXmed AG and its competitors.
Is bioXXmed AG's Beta too high?
bioXXmed AG's current Beta is 0.4911. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's Beta compare to VRTX and REGN?
bioXXmed AG's Beta of 0.4911 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for bioXXmed AG and its competitors. bioXXmed AG's current Beta is 0.4911. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current Beta is 0.4911. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current Beta is 0.4911 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioXXmed AG (HAM:T5O) Overvalued in 2026?

Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued. The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07. GuruFocus considers bioXXmed AG to be Possible Value Trap.

Key valuation signals for HAM:T5O:

  • Beta: 0.4911
  • GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
  • GF Score™: 33/100 with 3 warning signs

No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


bioXXmed AG Business Description

Other Exchanges T5O:Germany
Address Riedstrasse 2, Darmstadt, HE, DEU, 64295
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
33GF Score

Get the complete analysis for HAM:T5O

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€9.07
GF Value